Movement Disorders

*You must be registered for the ANA2021 Virtual Annual Meeting to access the live SIG Series sessions.

Date/Time ET: Wednesday, December 15, 2021 - 11:30 AM  – 1:00 PM

Description: This year's Movement Disorders Special Interest Group session will focus on the non-neuronal aspects of neurodegeneration in movement disorders. While neuronal loss is the primary focus of most research in neurodegeneration, studies in these diseases demonstrate that neuron-glial interactions may have a key role in the pathogenesis of these diseases. Microglia, astrocytes and oligodendrocytes contribute to the progressive neuropathological abnormalities manifested in these movement disorders through various mechanisms, including neuro-inflammation and excitotoxicity. These mechanisms have been uncovered using various systems; including cells isolated from human tissue for analysis of gene expression, human induced pluripotent stem cells, rodent primary glial cell culture models expressing the various disease causing proteins, and mouse models genetically or virally expressing the abnormal proteins. These studies have revealed these cells to play roles in the progression of the neuropathology in these diseases, the propagation of the mutated protein from one cell or one brain region to another or abnormal neuroinflammatory responses. Thus, the contribution of astrocytes, microglia and oligodendrocytes to the phenotypes manifested in these diseases is an important growing area of research and understanding their contribution to neurodegeneration may provide new avenues for therapeutic intervention.

Chair: Anne-Marie Wills, MD, MPH, Massachusetts General Hospital, Harvard Medical School

Co-Chair: Michelle Gray, PhD, University of Alabama at Birmingham


  • Following this session participants will have a better understanding of the contribution of glia and microglia to neurodegenerative disorders such as Parkinson's, HD and tauopathies, the influence of neuroinflammation on these diseases; synuclein and tau pathology as they relate to non-neuronal cell types; potential novel therapeutic targets for diseases


Targeting Immune Dysfunction and Inflammation in Parkinson’s Disease


Malu Gamez Tansey, PhD

University of Florida

Monogenic Hub of the Global Parkinson’s Genetics Program (GP2): The 500 Genomes Pilot Project

Oral Presenter:

Niccolo Mencacci, MD, PhD

Northwestern University

Astrocyte Contributions to Differential Patterns of Pathological Tau Spread in AD and PSP


Wendy Noble, PhD

King's College London

Patterns of Cortical Tau Pathology in LBD and PSP: A Multi-center Digital Histology Study

Oral Presenter:

David Coughlin, MD, MTR

University of California San Diego

Formation and Popagation of Distinct Alpha-Synuclein Strains


Joel Watts, PhD

Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto

Effect of Hydrogen Sulfide on Alpha-Synuclein Aggregation

Oral Presenter:

Tritia Yamasaki, MD, PhD

University of Kentucky

Continuing Medical Education

The American Neurological Association hosts a wide range of educational programs. These programs seek to enhance the development and success of those pursuing a career in academic neurology at all levels. There are educational offerings to benefit those at the beginning stages of their careers, including students and those in their first faculty position, as well as those looking for best practices in Chair level positions. These programs seek to enhance attendee success in the field of academic neurology and to contribute to the overall education of neurologists and neuroscientists.

The Special Interest Groups offer CME to eligible participants. Click here to see a complete breakdown of how many credits are available per session.

ACCME Accreditation, AMA Designation, and MIPS Statements **Pertaining to Each Session Awarding CME**

The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Neurological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).


Instructions For Obtaining CME

Following the event, the evaluation and credit claiming system will open in OnDEC. Please complete the online evaluation by 12/31/2021 to obtain CME credit. You will be provided with a certificate after completing the evaluation. If you have any questions, please contact the ANA Meeting Coordinator at:

Click here to see a complete breakdown of how many credits are available per session.

Financial Disclosure Statements

The planners and faculty for this activity do not have any relationships to disclose unless listed here. Any relevant relationships with ACCME-defined ineligible companies will be mitigated according to ACCME Standards prior to the start of the activity.

Disclosure of Commercial Support

ANA received educational grants from the following ACCME-defined ineligible companies to support the CME aspects of this event: Added as confirmed.

DISCLAIMER: The ANA does not endorse or affiliate with third-party companies, products or services including those that may have elected to support the Special Interest Groups.